RxDoctor Payments DataLook up a doctor →

Harvey Tatum, MD

Gastroenterology · Tulsa, OKNPI 1659333623

Payments from drug & device makers

$2,565,036in general payments, 2019–2025

Across 1,574 payments — averaging $1629.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1M
  • Vanda Pharmaceuticals Inc.$794K
  • Takeda Pharmaceuticals U.S.A., Inc.$347K
  • Gilead$153K
  • Novartis$87K
  • Genentech, Inc.$79K
  • plus $102K from 34 others
$939in research payments, 2019–2025

Across 10 payments — averaging $93.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$939

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,565,036 in reported general payments places this provider in the 95th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$88,142
Medicare patients
417
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →